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Non-syndromic oral clefts are considered ‘complex’ or ‘multifactorial’ in that both 
genes and environmental factors contribute to the etiology. Thus far, several genes 
such as TGFA, MSX1, TGFB3, D4S192, RARA, MTHFR, RFC1, GABRB3, PVRL1, 
and IRF6 were found to be associated with oral clefting. However, environmental 
factors such as maternal smoking or drug treatment in pregnancy especially during the 
early stage of fetal development can influence the disease risk. Thus, barrier organs in 
mother and fetus play crucial role in controlling the fetal exposure to potentially toxic 
xenobiotics. ATP-binding cassette (ABC) proteins are active efflux transporters 
regulates the traffic of xenobiotics across cells in maternal barrier organs and placenta 
as a fetal barrier organ.  
Family based association study and case-control study were conducted to investigate 
the role of potentially functional polymorphisms within four ABC transporter genes, 
namely ABCB1 (e12/C1236T, e21/G2677T/A, e26/C3435T), ABCC1 (5'FR/G-260C), 
ABCC2 (e1/C-24T, e10/G1249A, e25/G3542T), and ABCG2 (e2/G34A, i9/T-357C, 
e5/C421A) in susceptibility to non-syndromic orofacial clefting. For the family based 
study, 150 nuclear families of single affected offspring with oral clefs were recruited 
from Singapore and Taiwan. The phenotype of interest included all forms of non-
syndromic orofacial clefts including cleft lip (unilateral or bilateral) with or without 
cleft palate (CL/P), cleft palate, or both. In the recruited families, parents were all 
unaffected with oral clefts.  
In the case-control study, the affected member from the recruited family will represent 






The SNP genotype data of 128 oral cleft Chinese children as well as 129 Chinese 
mothers with oral cleft proband were separately compared against the control group.  
Genomic DNAs extracted from the families’ peripheral blood and the controls’ cord 
blood samples were genotyped for the target SNPs through multiplex PCR, multiplex 
minisequencing, sequencing, and TaqMan® SNP Genotyping Assay.  
An extended transmission disequilibrium analysis on the genotype data of the families 
revealed that only SNPs within the ABCB1 gene (e12/1236, e21/2677, and e26/3435), 
but not SNPs in other ABC genes were significantly associated with orofacial clefting 
(P<0.05). Interestingly, the results of the family based study were validated by the 
case-control analysis, which showed significant association for the SNP C1236T even 
after correction for multiple testing in children with oral clefts using Fisher's exact 
test. However, there was no significant difference in the SNPs allele distribution 
between the mothers of the oral clefts and the controls, suggesting the fetal ABCB1 
genotype not the maternal genotype is crucial in the disease risk. Moreover, in 129 
Chinese families with oral cleft offspring, no significant difference was observed 
when proportions of the homozygote maternal genotypes were compared with the 
paternal genotypes in the presence of a homozygote proband for the target SNPs, 
suggesting no synergistic effect for the maternal genotype on fetal genotype in the 
disease vulnerability.  
The findings of this study can favor the important role of the placental ABCB1 in 
protecting the fetus at the time when lip and palate are forming and suggest that fetal 
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1 INTRODUCTION  
 
Placenta is the organ that brings into close apposition the blood circulations of two 
human beings, mother and fetus for exchanging of nutrients and gases between mother 
and fetus and removing fetal waste products and xenobiotics including drugs. The 
human placenta is formed by both fetal (chorionic plate and chorionic villi) and 
maternal tissues (decidua basalis). The placenta consists of syncytiotrophoblast and 
cytotrophoblast (or Langerhans) layers. The apical membrane of the 
syncytiotrophoblast is directly bathed in the maternal blood while the basolateral 
surface is in contact with either the discontinuous cytotrophoblast layer, with stromal 
tissue or with fetal blood vessels. Thus, the passage of toxins or nutrients from 
maternal to fetal circulation requires translocation across the brush border (apical) and 
basolateral membrane of the syncytiotrophoblast, as well as the continuous 
endothelium of the fetal capillaries. Transporter proteins, such as ATP-binding 
cassette transporters (ABC-transporter) are located at apical and basolateral surfaces 
of syncytiotrophoblast and endothelial cells of fetal capillaries (Figure  1-1). These 
proteins are able to efflux environmental toxicants or drugs ingested by the mother to 
the maternal circulation. Therefore, they are supposed to be a functional part of the 
placental barrier and the expression of transporter proteins within these structures is 
important in protecting the fetus from toxic xenobiotics. Because the trophoblast cells 
forming the materno-fetal barrier are of fetal origin, expression of transporter proteins 
in placental is determined by the fetal genotype. Hence, placenta is considered the first 












Figure  1-1  Schematic of placental localization and function of MDRPs. ATP hydrolysis 
drives the efflux of Antiepileptic drugs (Atkinson et al. 2007) [Reprinted, with permission]. 
 
 
Functional genetic polymorphisms in major ABC-transporter genes expressed in the 
placenta may impair the detoxification role of these proteins in protecting the fetus 
from feto-toxic substances, thus increasing the risk of complex genetic disorders 
mediated by xenobiotics exposure. In the current study, we aimed to search the 
association between functional polymorphisms in four members of ABC-transporter 
family, ABCB1; ABCC1; ABCC2; ABCG2, with orofacial clefting in which both 
genes and environmental factors influence the disease risk.  
Orofacial clefts (i.e., cleft lip [CL], cleft lip and palate [CLP], or cleft palate [CP] 
alone) are one of the most common birth defects (approximately one case in every 
500-550 births) and varies widely in severity. Pathologically, orofacial clefts are 
divided into syndromic ,babies having other birth defects, and nonsyndromic.  
In normal development, facial morphogenesis begins with migrating of neural crest 








processes and in the normal situation; the processes grow into an open space by means 
of migration and multiplication of neural crest cells. The formation of a baby's lip will 
close by about 5 to 6 weeks and the palate will close by about 10 weeks after 
gestation. The cleft may happen because of reducing migration, multiplication, or both 
of neural crest cells, thus preventing merging between the medial nasal and maxillary 
processes around 5 weeks' gestation, or it can be because of killing some cells that are 
already in that location on one or both sides.  
However, the cleft may affect only the upper lip, or it may more deeply extend into 
the maxilla and the primary palate. Generally, a cleft lip/palate occurs more often than 
the isolated cleft palate.  
Being a complex disorder, orofacial malformations can be influenced by both 
individual and environmental factors such as:  
1. Race: Asians and some groups of native Americans are appeared to be more 
affected with cleft lip/palate, but the risk for isolated cleft palate appears similar in all 
racial groups.  
2. Gender: cleft lip/palate occurs more frequently in males, but isolated cleft palate 
occurs more frequently in females. 
3. Genetics: studies have revealed association between nonsyndromic orofacial clefts 
and a number of genes, such as TGFA, MSX1, TGFB3, D4S192, RARA, MTHFR, 
RFC1, GABRB3, PVRL1, and IRF6. However, causal genes may interact with one 
another and/or with environmental risk factors.  
4. Mother's health: maternal illness or infection as well as a deficiency of folic acid 
may be liable for these anomalies. Studies also suggest a link between development of 
cleft lip/ palate and maternal medication (such as antiepileptic drugs), maternal 








However, a cleft lip/palate develops when exogenous factors, such as toxic drugs, 
interact with a genetically susceptible genotype, during the early stage of development 
(i.e., 5 or 10 weeks after gestation), which is a critical period for fusing the processes 
and the palate.  
1.1  ATP Binding Cassette Transporter  
 
ATP-binding cassette transporters (ABC-transporter) are members of a largest protein 
superfamily in both prokaryotic and eukaryotic organisms. Currently, more than 49 
members of this super-family have been identified in human, which are classified into 
seven distinct subfamilies based on the organization of their domains and amino acid 
homology. The subfamily designations are as follows: ABCA, ABCB, ABCC, ABCD, 
ABCE, ABCF, and ABCG. Members of the ABCB subfamily can be referred to as the 
“MDR-ABC transporters” and members of ABCC subfamily can be referred to as the 
“MRP-ABC transporters”. 
These transmembrane proteins utilize the energy of adenosine triphosphate (ATP) 
hydrolysis for the translocation of various substrates, including metabolic products, 
lipids and sterols, and drugs across extra- and intracellular membranes. Given their 
vital role, human ABC transporters are medically important. They are found to be 
involved in several Mendelian diseases and complex genetic disorders, including 
cystic fibrosis, neurological disease, immune deficiencies, retinal degeneration, 
cholesterol and bile transport defects (Dubin-Johnson syndrome), Tangier disease, 
anemia, and drug response phenotypes that arise from polymorphisms in ABC genes 
and rarely due to complete loss of function of single ABC proteins (Pohl et al. 2005). 
ABC transporters are also found to be responsible for multiple drug resistance (MDR) 








depressants, anti-pyschotics, anti-viral drugs, and other drugs. Studies have revealed 
that these proteins are overexpressed in tumor cells, thus conferring them resistance to 
chemotherapy. Table 1 shows a partial list of drugs transported by these proteins. 
1.1.1 Structure and Function   
 
All ABC transporters consist of two distinct domains, the hydrophobic transmembrane 
domain (TMD) and the hydrophilic nucleotide-binding domain (NBD). The TMD, 
also known as membrane-spanning domain (MSD) or integral membrane (IM) domain 
embedded in the membrane bilayer. It recognizes a variety of substrates and 
undergoes conformational changes to transport the substrate across the membrane. 
The sequence and architecture of TMDs is variable, reflecting the chemical diversity 
of substrates that can be translocated, as TMDs is believed to provide the specificity 
for the substrate.  
NBD, also known as nucleotide-binding fold (NBF) is a site for ATP binding. The 
NBDs are located in the cytoplasm and have a highly conserved sequence. Therefore, 
these proteins are classified as ABC transporters based on the sequence and 
organization of their ATP-binding domain(s).  
ABC transporters are either full transporters or half transporters. The structural 
architecture of full ABC transporters consists minimally of two TMDs and two NBDs, 
while half transporters consist of one TMD and one NBD domains (Figure  1-2 B). The 
half transporters must form either homodimers or heterodimers in order to be 
functional.  
ABC transporters are an active transporter, which use the energy of ATP to drive 








transports molecules (Hollenstein et al. 2007), In eukaryotes, they mostly act as 
effluxers, moving substrates from inside to outside of the membrane (Dean et al. 
2001). These proteins are found to be located in the membranes of healthy cells where 
they facilitate the transport of various endogenous and exogenous substances.  
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Figure  1-2  A. Diagram of the typical structure of an ABC gene (Marzolini et al. 2004) 
[Reprinted, with permission]. B. Structure of half and full transporters (CM: cellular 




For the current study four members of the human ATP-binding cassette (ABC) 
transporter family, namely  ABCB1, ABCC1, ABCC2, and ABCG2 were of particular 
interest because they are known to be highly expressed in tissues important for 
absorption (e.g., lung and gut), metabolism and elimination (liver and kidney). For 
instance, these ABC transporters limit the absorption of many drugs from intestine, 
and pump drugs from liver cells to bile. Therefore are capable to modulate the 
absorption, distribution, metabolism, excretion, and toxicity of xenobiotics in intra and 
extra-cellular environments. These proteins are also active effluxers in barrier site 
tissues (e.g., blood-brain barrier, blood-cerebral spinal fluid barrier, blood-testis 














for these transporters, thus are important in pharmacokinetics of various drugs. ABC 
drug transporters have their own unique profiles, but ABCB1, ABCC1, and ABCG2 
were reported to have overlapping tissue distribution and the substrate specificities 
(Gottesman, 2002). In pregnancy, the risk of maternal pharmacotherapy on the fetus 
can be influenced by the performance of these transporters. Collectively, it seems that 
these ABC transporters can play a crucial role during pregnancy in reducing the level 
of xenobiotics in maternal and fetal circulation, thereby protecting the developing 
fetus from exposure to potentially toxic compounds. There is substantial evidence that 
the four efflux pumps have overlapping functions in tissue defense.  
Recently, study of polymorphisms in ABC genes has greatly been regarded. There are 
numerous sequence variations in genes of the ABC transporter family. However, 
functional genomic studies and investigation of signatures of recent positive selection 
(RPS) have contributed to identify a number of functional Single Nucleotide 
Polymorphisms (SNP) within the genes. Functional SNPs that result in changes in 
mRNA or protein expression, protein activity, substrate specificity, or influence on 
bioavailability and therapeutic outcomes can increase susceptibility of individuals to 
the adverse effects of espousing to xenobiotic and interindividual differences in drug 
response. Therefore, genetic variation in these genes can be the cause or contributor to 
a wide variety of human disorders with Mendelian and complex inheritance.  
The following discussion and literature reports will be limited to aforementioned ABC 
transporters and important SNPs of them that are found to alter function or expression 






Table 1  Function and expression of ABCB1, ABCC1, ABCC2, and ABCG2 genes in human  
Name Alternative titles 
Chromosomal 















Brain, Kidney, Adrenal, 






Apical Multidrug Resistance   
Doxorubicin, daunorubicin, 
paclitaxel, topotecan, vinblastine,  
tamoxifen, etoposide, cefazolin, 
cefoperazone, erythromycin, 
verapamil, diltiazem, phenytoin, 
phenoxazine, perphenazine, 




loperamide, quinidine, digoxin, 























Epirubicin, Etoposide, Imatinib, 
CPT-11, SB-38, Arsenite, 
Colchicine, Methotrexate, 


















Doxorubicin, Epirubicin, Etoposide, 
Docetaxel, Paclitaxel, CPT-11, SN-




















Epirubicin, Etoposide, Gleevec, 
Flavopiridol, CPT-11, SN-38, 
Topotecan, Bisantrene, 






    
                                                                                
 
9 
1.2 ABCB1 (MDR1/ P-glycoprotein)  
 
1.2.1 Function and expression 
 
The human ABCB subfamily (MDR-ABC transporters) consists of 11 members, 
ABCB1 through ABCB11. Among these, ABCB1 (MDR1) is one of the largest 
proteins, consisting of about 1280 amino acids. The ABCB1 protein with a molecular 
weight (MW) of 170-kDa, is also referred to as P-glycoprotein (P-gp) and the gene is 
designated as ABCB1/MDR1. Human ABCB1 is found in the epithelia of many 
tissues, such as intestine, liver, kidney, blood-brain barrier, testis, lung, lymphocytes, 
hematopoietic stem cells, ovaries, and placenta (Figure  1-3). However, there is 
variability of expression of this transporter among tissues and within tissues among 
different population of cells. The expression of ABCB1 is modified by both genetic 
polymorphism and exogenous factors (drugs, diet) caused a broad interindividual 
variability. 
ABCB1 serves not only a crucial physiological role in protecting the cells against 
toxic compounds and metabolites, but it also plays a large role in distribution and 
elimination of many clinically important therapeutic substances. Substrates 
transported by ABCB1 include metabolic products, lipids, sterols, drugs (such as 
drugs used in cancer chemotherapy, hypertension, infection, allergy, 
immunosuppression, neurology, and inflammation) and other xenobiotics. Expression 
of ABCB1 in the endothelial cells of brain capillaries ,the blood-brain barrier, gives 
protection against penetration of toxic substances and drugs into the brain. Until now, 
attentions have been paid to the possible role of ABCB1 mutations in the pathogenesis 
of Alzheimer's and Parkinson’s disease.  
CHAPTER 1 
    
                                                                                
 
10 
It can be hypothesized that during pregnancy, ABCB1 in lung, small intestine, kidney, 
liver, and placenta is able to actively control drugs and other xenobiotics levels in 
maternal and subsequently fetal circulation, thereby limiting fetal exposure to 
potentially teratogenic substances. Hence, it is possible that genetic polymorphisms 
leading to variability in the transporter expression can cause interindividual variability 
in the fetal exposure at least to some extent. Studies of human term placenta have 
shown that ABCB1 is expressed at relatively high levels in the brush border (apical) 
of the syncytiotrophoblast but not in endothelial cells (Atkinson et al. 2003).  
It is known that the first trimester of gestational age is highly critical for the risk of 
embryonic exposure to potential teratogens and developing complex inherited 
abnormalities mediated by xenobiotics. Interestingly, in human, the mean expression 
of ABCB1/P-gp in placenta measured by Western blotting method in early (13-14 
gestation week) compared to the late (full-term) placentas was found to be two-times 
higher (Gil et al. 2005). Consistent with this report, Mathias et al. (2005) and Sun et 
al. (2006) have observed that the human placental P-gp expression appears to be up-
regulated in early pregnancy to protect the fetus from xenobiotic toxicity at a time 
when it is most vulnerable to such toxicity. Mathias et al. (2005) also reported that the 
decrease in P-gp expression in the term placenta could be related to human chorionic 
gonadotropin-β (HCG-β) expression. 
Additionally, studies in mice offer convincing evidence that P-glycoprotein plays an 
important role in protecting the fetus from xenobiotics. In an experiment performed by 
Lankas et al. (1998) in a subpopulation of the CF-1 mouse strain that contains 
spontaneous mutation in mdr1a gene revealed when pregnant dams were exposed to 
the teratogenic isomer of avermectin, a known substrate of P-gp, fetuses deficient in 
CHAPTER 1 
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P-gp ABCB1a (−/−) gene were 100% susceptible to cleft palate. Whereas, their (+/−) 
littermates were less sensitive (30% of fetuses with cleft palate) and homozygotes 
(+/+) fetuses with abundant P-gp were totally insensitive at the tested doses. The 
authors of the above study confirmed that the absence of the P-glycoprotein in the 
knock-out mice permitted greater amounts of antihelmintic avermectin, which is 
known to produce cleft palate in mice, to pass the placental barrier and induce 
significant cleft palate. They observed that the degree of chemical exposure of fetuses 
within each litter is inversely related to the expression of placental P-gp. Similarly, 
Smit et al. (1999) demonstrated that mice in which both the ABCB1 genes, ABCB1a 
and ABCB1b, were disrupted had a 2.4-, 7-, and 16-fold higher transplacental transport 
of ABCB1 substrates such as digoxin, saquinavir, and paclitaxel, respectively, as 




Figure  1-3  P-gp tissue distribution; Efflux activity associated with P-gp would reduce 
intestinal drug absorption while enhancing drug elimination through the liver and kidney. At 
barrier sites such as the blood-brain barrier, testes, or placenta, P-gp would limit tissue 
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1.2.2 ABCB1 gene polymorphisms 
 
The human ABCB1 gene is located on chromosome 7 and is composed of 28 exons.  
Although the variable expression of ABCB1 gene may be caused by different 
environmental factors, genetic polymorphisms of this gene are believed to represent 
the major source of the (interindividual) variability in the protein expression.  
Thus far, significant progress has been made in the discovery of ABCB1 
polymorphisms and the assessment of allelic frequencies. To date, about 62 single-
nucleotide polymorphisms (SNPs) have been identified in the human ABCB1 gene, 
including coding and noncoding regions of the gene 
[http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=5243]. It has been found that 
important single nucleotide polymorphisms (SNPs) and SNP haplotypes within this 
gene are variously associated with differences in ABCB1 expression, drug response, 
and disease susceptibility. Among discovered SNPs, three variations in exon 21 
(G2677T/A), exon 26 (C3435T), and exon 12 (C1236T) are of particular interest 
because they are in linkage disequilibrium, thereby forming a SNP haplotype which 
seems to be observed across all ethnic groups (Kim et al. 2001; Tanabe et al. 2001; 
Horinouchi et al. 2002). These three SNPs occur at high frequency (>10% minor allele 
frequency) in African-Americans, Caucasians, Chinese, Malays, and Indians. 
However, differences in the alleles’ frequency of these SNPs have been reported in the 
different ethnicities.  






    




Table 2  Allele frequencies of MDR1 exon 26, 21, and 12 polymorphisms in various ethnic 










(exon 12)   
Population No. C T G T A C T Study 
Caucasians                   
Caucasian, Italy 106 0.54 0.46 0.56 0.41 0.03   Furuno et al 
Caucasian, United States 37 0.46 0.54 0.54 0.46 ND 0.58 0.42 Kim et al 
Caucasian, Germany 188 0.52 0.48    0.62 0.38 Hoffmeyer et al 
Caucasian, Germany 461 0.46 0.54 0.56 0.42 0.02 0.59 0.41 Cascorbi et al 
Caucasian, Germany 67 0.49 0.51 0.56 0.40 0.04 0.66 0.34 Siegmund et al 
Caucasian, Germany 537 0.50 0.50      Schaeffeler et al 
Caucasian, Germany 50 0.49 0.51 0.52 0.38 0.10   Gerloff et al 
Caucasian, Poland 103 0.51 0.59      Drozdzik et a 
Caucasian, Russia 290 0.46 0.54 0.55 0.42 0.03   Gaikovitch et al 
Caucasian, Spain 408 0.52 0.48      Bernal et al 
Caucasian, United Kingdom 200 0.47 0.53      Siddiqui et al 
Caucasian, United Kingdom 190 0.48 0.52      Ameyraw et al 
Caucasian, New Zealand 160 0.47 0.53      Roberts et al 
Portuguese 100 0.43 0.57      Ameyaw et al 
Asians          
Japanese 50 0.57 0.43      Schaeffeler et al 
Japanese 48 0.51 0.49 0.36 0.42 0.22 0.35 0.65 Tanabe et al 
Japanese 114 0.61 0.39      Sakaeda et al 
Japanese 117 0.62 0.38 0.44 0.36 0.20   Horinouchi et al 
Japanese 13 0.54 0.46 0.39 0.46 0.15   Moriya et al 
Chinese 132 0.53 0.47      Ameyaw et al 
Chinese 96 0.47 0.53 0.38 0.50 0.12 0.28 0.72 Chowbay et al 
Chinese 104 0.60 0.40 0.50 0.44 0.06 0.31 0.69 Tang et al 
Chinese 98 0.46 0.54      Balram et al 
Malay 92 0.49 0.51 0.53 0.44 0.03 0.34 0.66 Chowbay et al 
Malay 93 0.63 0.37 0.58 0.36 0.06 0.31 0.69 Tang et al 
Malay 99 0.48 0.52      Balram et al 
Indian 87 0.37 0.63 0.33 0.60 0.07 0.33 0.67 Chowbay et al 
Indian 68 0.40 0.60 0.34 0.62 0.04 0.40 0.60 Tang et al 
Indian 93 0.38 0.62      Balram et al 
Filipino 60 0.59 0.41      Ameyaw et al 
Saudi 96 0.55 0.45      Ameyaw et al 
Southwest Asian 89 0.34 0.66      Ameyaw et al 
Africans          
Ghanaian 172 0.90 0.10      Schaeffeler et al 
Ghanaian 206 0.83 0.17      Ameyaw et al 
Kenyan 80 0.83 0.17      Ameyaw et al 
Sudanese 51 0.73 0.27      Ameyaw et al 
African American 41 0.78 0.22      Schaeffeler et al 
African American 88 0.84 0.16      Ameyaw et al 
African American 23 0.74 0.26 0.85 0.15 ND 0.85 0.15 Kim et al 
 
   *ND, Not done. 
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Linkage studies have revealed that in Chinese, Malays, Indians and Caucasians but not 
African Americans, the T allele of the SNP e26/3435 is frequently linked with the T 
alleles of the SNPs e21/2677(G/T/A) and e12/1236(T/C). The SNP haplotype 
C1236T-G2677T-C3435T (i.e., T1236-T2677-T3435) is frequent in European- 
Americans, whereas the SNP haplotype C1236C-G2677G-C3435C (i.e., C1236-
G2677-C3435) is frequent in Africans (Kim et al. 2001; Tang et al. 2002; Ozawa et al. 
2004). Functional genomic studies have disclosed that these variations are associated 
with altered function and expression of P-gp. The two SNPs in exon 26 and 12 are 
located at a nonpromoter position in the ABCB1 gene but occur in the functionally 




Figure  1-4  Two-dimensional structure of ABCB1 with locations of amino acid replacements 
and two frequent synonymous SNP (italic); NBD=nucleotide-binding domain (Cascorbi et al. 
2001) [Reprinted, with permission]. 
 
However, C1236T and C3435T polymorphisms are silent SNPs, as they do not change 
the amino acid sequences of the encoded protein. The C1236T polymorphism changes 
a GGC codon to GGT at amino acid position 412 (both encode Gly), and the C3435T 
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polymorphism changes ATC to ATT at position 1145 (both encode Ile). 
The SNP in exon 21 at position 2677 is a nonsynonymous polymorphism that results 
in two distinct amino acid changes, namely, Ala893Ser (G2677T) and Ala893Thr 
(G2677A). The C3435T and C1236T SNPs were found to be linked to the 
nonsynonymous SNP e21/2677(G/T/A), suggesting that functional differences in P-gp 
attributed to the synonymous SNPs (exon 26 and 12) may be due to the 
nonsynonymous SNP in exon 21 (G2677T/A) (Tanabe et al. 2001). Moreover, an 
interesting study by Kimchi-Sarfaty et al. (2007) has showed the way that the 
synonymous SNP C3435T can still be functional. The author favored a hypothesis that 
the polymorphism represents a codon, which is rarer than that of the wild-type 
ABCB1, causing a translation pause and an alteration in the rate of translation. 
Therefore, even in similar mRNA and protein levels observed for the wild type and 
polymorphic gene, the polymorphism can alter the structure of substrate and inhibitor 
interaction sites in the protein.  
The synonymous SNP in exon 26 (C3435T) was first shown to be associated with 
decreased expression of P-gp in the duodenum of subjects with the T allele (variant) 
compared to those with the C allele (wild type) (Hoffmeyer et al. 2000). However, 
subsequent studies suggested that the decreased expression may be due to the 
nonsynonymous SNP in exon 21 (G2677T/A) (Kim et al. 2001). Consistent with this 
finding, Ameyaw et al. (2001) observed marked differences in the allele frequency of 
the exon 26 SNP (C3435T) between African and Caucasian-Asian populations. The 
authors reported the allelic frequency of C allele (wild type) is high in African 
populations (80%) compared to that in Caucasian-Asian populations (45-55%). 
Because the C allele was initially found to be associated with a higher expression of P-
gp, it was hypothesized that the observed higher frequency of the CC genotype in 
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Africans may have resulted from a selective advantage offered by this genotype 
against gastrointestinal tract infections (Marzolini et al. 2004).  
In another study, Johne et al. (2002) reported increased digoxin plasma concentrations 
in TT carriers of subjects, suggesting greater intestinal drug absorption due to low 
intestinal P-gp levels. They also demonstrated the effect was stronger in 
2677GG/3435TT carriers.  But many later findings were not consistent with this 
earlier findings, such as reports of elevated expression of ABCB1 mRNA in Japanese 
subjects carrying the 3435T allele (Nakamura et al. 2002) or Caucasian subjects 
carrying the 3435T allele (Siegmund et al. 2002). Conflicting data have also been 
reported for the effect of exon 21 SNP (G2677T/A). However, one explanation for 
these discrepancies might be haplotype diversities observed for the SNP C3435T with 
the two other SNPs in exon 12 and 21 among different populations. 
In human liver, Wang* et al. (2005) have showed that the mRNA expression of the 
3435C allele is significantly higher than that of the 3435T allele. However, they found 
no association between C1236T and G2677T/A SNPs with lower mRNA levels. The 
authors have concluded that the C3435T SNP may change mRNA stability and 
therefore mRNA expression in the liver. In addition, Song et al. (2006) observed that 
not only the SNP 3435C but also the 2677G allele was associated with higher hepatic 
ABCB1 mRNA expression and interestingly the GC haplotype pair carriers had a 
significantly higher hepatic ABCB1 mRNA expression.  
In contrast, another study on non-cancerous kidney cortex tissues by Haenisch et al. 
(2007) revealed that homozygous samples for the SNP 3435C had lower ABCB1 
mRNA/18S rRNA ratio compared to heterozygotes or homozygotes 3435T allele 
carriers. Moreover, they reported that another ABCB1 polymorphism at 
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e21/2677(G/T/A) showed a clear correlation with the mRNA expression. The authors 
observed samples carrying at least one 2677T/A allele had higher ABCB1 mRNA 
expression levels compared to samples homozygous for 2677G. Likewise, Meissner et 
al. (2004) reported in human heart tissue the 2677T/A variant was associated with 
elevated ABCB1 mRNA levels. However, in placenta findings are different.  Tanabe 
et al. (2001) by Western blotting in 100 full-term placentas obtained from Japanese 
women have found that individuals having the G2677(A,T) allele has less placental 
trophoblast ABCB1 expression. They also reported that 93.8% of their subjects who 
had a C3435T allele, also were carrier of a mutant allele from the SNP G2677(A,T), 
suggesting an association between the two polymorphism. In addition, the authors 
observed an association between greater placental ABCB1 expression in homozygous 
CC samples for SNP C3435T compared to CT and TT genotypes, but they attributed 
this finding to the nonsynonymous SNP G2677(A,T). However, according to a recent 
study by Kimchi-Sarfaty et al. (2007), the SNP C3435T can be functional regardless 
of its linkage to the SNP G2677(A,T). Moreover, Hitzl et al. (2004) reported that the 
placental P-gp expression was lower when both mother and child were carriers of 
3435T compared to levels obtained for pairs of 3435C, although they found no 
influence on the mRNA levels by these polymorphisms. They also found that term 
placentas from mothers carrying both polymorphisms (3435T and 2677T; TT/TT) had 
a significantly lower P-gp expression compared to placentas of wild-type individuals.  
Nonetheless, as ABCB1 expression is thought to decrease with advancing of 
gestational age, these two studies would have been more productive if the authors had 
included preterm placentas in their studies instead of placental tissues from late 
normal pregnancies. Furthermore, Sherif et al. (2007) have observed that term but not 
preterm placentas, which are carriers of 2677T/A (homozygous or heterozygous) have 
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significantly less P-gp expression compared to homozygous placentas for 2677G.  
ABCB1 SNP C1236T also found to be functionally important. In Asian subjects, 
contrary to Caucasians, the T allele of this SNP is more frequent than the C allele. 
Moreover, the number of observed haplotype combinations is different among diverse 
populations (Tang et al. 2002). In a study by Mathijssen et al. (2003), upon 
administration of Irinotecan to 65 cancer patients, the homozygous TT individuals for 
this polymorphism demonstrated a significant association with increased exposure to 
irinotecan and its active metabolite SN-38. In addition, Aird et al. (2007) have showed 
in 3T3 isogenic fibroblasts, mutation at position 1236 can significantly alter ABCB1 
expression, regardless of additional mutations at positions 2677 and 3435. Consistent 
with these reports, recently Vaclavikovaa et al. (2008) observed that breast cancer 
patients with variant alleles in exons 12 (1236) and 26 (3435) had significantly lower 
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Table 3  Positions, sequences, and frequencies of MDR1 variants in human placentas (cDNA) and genomic DNAs and genomic DNAs  




Placental cDNA (n = 100) 
 












 SNP          Exon/Position  
Wild Type (WT) Mutation (M) 
Effect 
W/W W/M M/M W M W/W W/M M/M W M 
 
        
       % 
   
       % 
T1236C      12/1236  agggTctga agggCctga Gly412Gly 50 31 19 65.5 34.5 21 20 7 64.6 35.4 
               
               
G2677T      21/2677  aggtGctgg aggtTctgg Ala893Ser 14 (G/G) 35 (G/T) 16 (T/T) 43.0 39.0 (T) 9 (G/G) 8 (G/T) 10 (T/T) 36.5 41.7 (T) 
               
G2677A   aggtActgg 893Thr  23 (G/A)   1 (A/A)  18.0 (A)  9 (G/A)   0 (A/A)  21.8 (A) 
       11 (A/T)     12 (A/T)   
               
C3435T      26/3435  agatCgtga agatTgtga Ile1145Ile 35 46 19 58.0 42.0 14 21 13 51.0 49.0 
               








     
1.3 ABCC1 (Multidrug-resistance related protein 1/MRP1) 
 
1.3.1 Function and expression 
 
The human ABCC subfamily (MRP-ABC transporters) consists of 12 members, 
ABCC1 through ABCC12. Of these, ABCC1 (MRP1) and ABCC2 (MRP2/cMOAT) 
are of interest in the current study. MRPs have three hydrophobic transmembrane 
domains (TMDs) which are also referred to as membrane-spanning domains (MSDs). 
ABCC1 is a large protein encoded by the ABCC1 gene, initially identified in the 
doxorubicin-resistant small cell lung carcinoma cell line H69AR that did not 
overexpress P-gp (Cole et al. 1992). The 190 kDa -ABCC1 protein is frequently 
highly overexpressed in multidrug resistant human tumor cell lines, usually as a result 
of amplification of the ABCC1/MRP1 gene. This protein confers resistance to a 
spectrum of anticancer drugs similar to ABCB1. However, unlike ABCB1, ABCC1 
transports drugs conjugated to glutathione. Moreover, ABCC1 serves as multispecific 
organic anion transporter for folate-based antimetabolites, anthracyclines, plant 
alkaloids and antiandrogens (Conseil et al. 2005).  
ABCC1 is expressed in most tissues with relatively high levels found at the blood-
brain barrier, blood-testes barrier, placenta, lungs, kidneys, skeletal muscle, spleen, 
and mononuclear cells and relatively low levels in the liver (Cole et al. 1998). As 
discussed on ABCB1, ABCC1 is also involved in protecting cells within the body 
against drugs, environmental toxins, and heavy metals. Moreover, ABCC1 has also 
been shown to contribute to cellular anti-oxidative defense system and inflammation 
(Hipfner et al. 1999; Leslie et al. 2001). In most tissues, ABCC1 is localized to the 
basolateral cell membrane. Thus, it pumps its substrates into the interstitial space 
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rather than excreting them into the bile, urine, or gut (Borst et al. 1999; Borst et al. 
2000). Because of the basolateral expression of ABCC1 this transporter could be 
important for transport of endogenous substrates, including nutrients (e.g., folic acid) 
and hormones (e.g., steroid conjugates) (Hooijberg et al. 2004; Ifergan et al. 2004). In 
the placenta, ABCC1 is predominantly expressed in fetal blood vessel endothelial 
cells but less on the basolateral surface of the syncytiotrophoblast structure. Being in 
such strategic locations, ABCC1 is able to prevent or limit entry of organic anions and 
xenobiotics, such as antiepileptic drugs into the fetal circulation.  
Moreover, ABCC1 plays an important role in nutrient absorption and protection of the 
trophoblast from toxic fetal waste products such as bilirubin and conjugated bile salts 
(St-Pierre et al. 2000; Atkinson et al. 2003; Nagashige et al. 2003; Gennuso et al. 
2004) (Figure  1-1). The analysis of human first and third (term) trimester placenta 
disclosed that the placental ABCC1 had a four-fold increase in the third as compared 
with first trimester placental samples (Pascolo et al. 2003).  
As discussed previously, folic acid deficiency can increase the risk of orofacial 
clefting. It can therefore be hypothesized that the impaired role of the placental 
ABCC1 in nutrient absorption may increase the risk of facial malformations. In 
addition, placental ABCC1 like ABCB1 is able to give protection to the fetus against 
antiepileptic drugs and other potentially toxic xenobiotics that increase the risk of 
orofacial clefts.  
1.3.2 ABCC1 gene polymorphism 
 
The human ABCC1 gene is located on chromosome 16 and is composed of 31 exons 
and 30 introns. Thus far, more than 70 SNPs have been identified in exonic, intronic 
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and promoter regions of the gene in individuals from five different populations, 
namely, Chinese, Malays, Indians, European Americans, and African Americans. Of 
these SNPs, a few have showed functional consequences, which might account, in 
part, for inter-individual and population differences in response to various drugs. Non-
synonymous SNPs identified at ABCC1 are less than 10%; however, synonymous or 
intronic SNPs may still affect ABCC1 expression or function through the alteration of 
the mRNA splicing, stability or folding. Additionally, polymorphisms at the 5’UTR 
and 3’UTR may influence promoter activity and hence gene expression or mRNA 
transcript stability.  
For the current study, SNP 5'FR/G-260C, which resides in the promoter region of 
ABCC1 was selected as target SNP.  SNP analysis by Wang et al. (2005) has showed 
evidence of recent positive selection (RPS) for this polymorphism in European-
Americans. In their study on different ethnicities, among approximately 480 
individuals sampled from Chinese, Malay, Indian, European-American, and African-
American populations, high haplotype frequency extended haplotype homozygosity 
was observed for allele G of the SNP in European-Americans. However, the authors 
found weak linkage disequilibrium (LD) in the presence of the high haplotype 
diversity, suggesting a genomic evidence of positive selection for SNP 5'FR/G-260C 
in the European-Americans. Furthermore, in vitro promoter-reporter assay strikingly 
revealed that the G-containing promoters had significantly lower promoter activity 






      
 
1.4 ABCC2 (Multidrug-resistance related protein 2/ MRP2) 
 
1.4.1 Function and expression 
 
ABCC2 with a MW of 190 kDa and 1545 amino acids is the largest MRP encoded by 
the ABCC2 gene. The protein is localized in the apical luminal membrane of polarized 
epithelial cells of several excretion organs like liver, intestine, and kidney, as well as 
in blood-brain barrier and placenta (Table 1). 
Studies in hepatocytes have shown that ABCC2/MRP2 is involved in exporting a 
variety of both conjugated and unconjugated anionic compounds into bile. Moreover, 
the protein was found to be involved in multi drug resistance in diverse tissues. The 
substrate specificity of ABCC2 is similar to that of ABCC1, and it includes 
glutathione conjugates such as bilirubin glucuronides, and a number of conjugated 
drug metabolites. Previous studies have also shown that Dubin-Johnson syndrome 
(DJS) ,an autosomal-recessive disorder, is linked to the absence of ABCC2 in human 
liver, resulting in symptomatic conjugated hyperbilirubinaemia. Affected individuals 
have life-long low-grade jaundice, which may be aggravated by alcohol, pregnancy, 
infection, and other environmental factors.  
In human placenta, ABCC2 is also localized at the apical membrane of 
syncytiotrophoblasts (facing maternal blood). ABCC2 is likely responsible for 
preventing the passage of conjugated metabolites of drugs, xenotoxins, and 
endogenous toxins (e.g., bilirubin) from maternal to fetal circulation. In addition, 
ABCC2 is potentially important for the passage of conjugated toxic fetal waste 
products from fetal to maternal circulation for excretion in maternal bile or urine. 
Therefore, the multidrug transporter ABCC2 may be also a functional part of the 
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“placenta barrier”. Contrary to ABCB1, ABCC2 is increasingly expressed with 
advancing pregnancy, suggesting ABCC2 may be more important than ABCB1 in late 
pregnancy (Schwabedissen et al. 2005; Sun et al. 2006; May et al. 2008). Therefore, 
the placental ABCC2 can provide protection to mature fetus against maternal 
pharmacotherapy and waste products produced by the fetus.    
1.4.2 ABCC2 gene polymorphism 
 
Human ABCC2 gene contains 32 exons and maps to chromosome 10. Similar to other 
discussed ABC transporters, polymorphisms of ABCC2 can result in interindividual 
differences in transport and excretion activity of this protein.  
Among ABCC2 SNPs, 3 polymorphisms at positions -24, 1249, and 3542 SNP were of 
interest for this study. These SNPs have previously been examined in previous studies 
for evidence of functional significance or positive selection.  
The SNP C-24T resided in the promoter region of ABCC2 have showed an effect on 
ABCC2 mRNA expression in normal kidney cortex (Haenisch et al. 2007). The 
authors observed the homozygous samples of -24C allele had higher median ABCC2 
mRNA/18S rRNA ratios than heterozygotes and homozygotes -24T carriers. 
However, no association found between this ABCC2 SNP and protein expression in 
the tissue samples.  
In contrast, Wang et al. (2007) have reported human liver samples with CT/TT 
genotype exhibits significantly higher ABCC2 mRNA expression when compared 
with liver samples with the CC genotype. They also found evidence of recent positive 
selection (RPS) for the T allele of this SNP in the absence of multiple test correction. 
Because SNP e1/C-24T resides at the promoter region of ABCC2, the authors also 
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performed a promoter-reporter assay in four different cell-lines. They found that this 
polymorphism affected ABCC2 promoter activity and the RPS T-allele of SNP e1/C-
24T mediated higher ABCC2 promoter activity in several cell-lines tested. However, 
earlier study by Schwabedissen et al. (2005) failed to show the effect of this promoter 
SNP on ABCC2 expression in human placenta.  
The exonic SNP e10/G1249A, which involves a conservative amino acid change 
(V471I), was reported by Schwabedissen et al. (2005) to result in decreased ABCC2 
mRNA levels in preterm placentas. The authors found that the 1249 AA genotypes 
were associated with a lower level of ABCC2 mRNA in the placentas of preterm 
babies. However, no significant difference of mRNA levels was observed in term 
placentas, suggesting that the mature fetus can take advantage of better protection 
against xenobiotics or drugs that are ABCC2 substrates. Moreover, it can be 
hypothesized that the expression of the placental ABCC2 might be influenced by some 
factors other than the genetic polymorphism in term pregnancy, such as maternal or 
placental hormones that tend to increase in late pregnancy. It would thus be interesting 
to examine the role of the pregnancy hormones in placental ABCC2 expression. 
Moreover, Wang et al. (2007) reported SNP e10/G1249A exhibited RPS when type I 
error reduction was not performed. 
Another ABCC2 SNP (G3542T) localized in exon 25 of the gene, has also showed 
evidence of recent positive selection in the study of Wang et al. (2007), suggesting 
that this polymorphism can be potentially functional. This SNP change arginine to 





      
 
1.5 ABCG2 (Breast Cancer Resistance Protein)  
 
1.5.1 Function and expression 
 
ABCG2 (also called BCRP/ABCP/MXR) is the second member of the G-family of 
ABC transporters. The protein is a half-size transporter containing a single MSD and 
NBD, that must homodimerize to acquire transport activity (Kage et al. 2002). 
ABCG2 was initially found to be overexpressed in a subline of human breast 
carcinoma MCF-7 cells. Later the protein was also found in a variety of stem cells, 
which can protect them from exogenous and endogenous toxins. Interestingly, up-
regulation of ABCG2 expression has been reported in tissues under low-oxygen 
conditions, suggesting the protection role of this transporter in cells and/or tissues 
from protoporphyrin accumulation under hypoxic conditions (Krishnamurthy et al. 
2006). In addition to such physiological functions, this protein has a crucial role in 
intestine, liver, placenta, and the blood-brain barrier. In normal human tissues, 
ABCG2 has been reported to be expressed at the apical surface of enterocytes in gut, 
liver hepatocytes, placental syncytiotrophoblast, in the capillaries of blood-brain 
barrier, breast, and to lesser extent in blood-testis barrier. (Ito et al. 2005; 
Schwabedissen et al. 2006; Maliepaard et al. 2001; Zhou et al. 2001; Eisenblatter et al. 
2002). However, there is no substantial evidence for the expression of ABCG2 in the 
human kidney. Moreover, this transporter is one of the major ABC proteins reported 
to play an important role in pharmacokinetic and pharmacodynamic of various drugs. 
ABCG2 has a high capacity for drug transport and wide substrate specificity, 
including mitoxantrone, prazosin, anthracyclines, camptothecins, and other therapeutic 
chemicals (Table 1).  
Studies in mice have demonstrated that placental ABCG2 can affect the transfer of 
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drugs across the placental barrier, suggesting a protecting role for these transporters 
for fetus against environmental toxicants or drugs ingested by the mother during 
pregnancy. Similarly, in human placenta, ABCG2 has been reported to be expressed at 
high levels and functionally active, indicating that ABCG2 can play as important role 
as ABCB1 in providing a protective role for the fetus (Kolwankar et al. 2005; 
Ceckova et al. 2006).  
Furthermore, Schwabedissen et al. (2006) has observed that the ABCG2 mRNA levels 
in human placenta at preterm (28±1 weeks) are approximately two times greater than 
that at term (39±2 weeks), and ABCG2 protein expression exhibits the same pattern as 
that of ABCG2 mRNA. However, other studies used a small sample size failed to 
show the changes in ABCG2 (protein or mRNA or both) expression in the placenta 
with advancing gestation.   
It would have been better if Schwabedissen et al. (2006) had measured ABCG2 
expression in the placentas of earlier than 28 weeks, because a study in mice has 
demonstrated that placental ABCG2 expression (protein and mRNA) peaks at mid 
gestation (Wang et al. 2006). If this also applies to the ABCG2 expression in human 
placenta, it can be concluded that the differential placental expression of ABCB1, 
ABCC1, ABCC2, and ABCG2 over the course of pregnancy can provide a 
compensatory mechanism for protection of fetus at different gestational stages. In 
other words, ABCB1 and ABCG2 are respectively crucial in early and mid gestation, 
but ABCC1 and ABCC2 seem to be more important in late pregnancy.  
1.5.2 ABCG2 gene polymorphism 
 
Human ABCG2 gene contains 15 exons and 16 introns maps to chromosome 4. 
Widely occurring single nucleotide polymorphisms in ABCG2 may affect on its 
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physiological function or absorption and distribution of drugs that are ABCG2 
substrates. ABCG2 SNP C421A at exon 5 has been extensively examined to search for 
its potential functions. This SNP occurs in the functionally important ATP-binding 
region of the ABCG2 between the Walker A and B motifs, resulting in substitution of 
the positively charged Lys residue for a neutral Gln residue. Imai et al. (2002) has 
showed that the C421A polymorphism is associated with significantly lower 
expression and activity of the encoded protein. However, the authors found no 
influence on ABCG2 mRNA expression. Moreover, studies have revealed that the 
SNP C421A can result in changes in the protein structure and alter ATPase activity 
and drug efflux properties of ABCG2 (Imai et al. 2002; Mizuarai et al. 2004; Morisaki 
et al. 2005; Kobayashi et al. 2005; Kondo et al. 2004). This SNP has also 
computationally exhibited an evidence of recent positive selection in the study of 
Wang et al. 2007.  
In Japanese placentas, Kobayashi et al. (2005) observed the mean ABCG2 protein 
level of the A421 homozygotes was approximately 50% of that of the C421 allele, and 
heterozygotes displayed an intermediate level. They further showed that this 
difference was likely caused by post-transcriptional regulation rather than changes in 
mRNA expression.  
Collectively, these findings suggest that the C421A polymorphism can decrease 
ABCG2 expression, leading to increased fetal xenobiotics or drug exposure. As shown 
in Table 4, the alleles’ frequency of this SNP greatly differs between diverse 
populations.  
In addition to the above SNP, G34A polymorphism in ABCG2 notably occurred at a 
relatively high frequency in most ethnic populations has been implicated to have 
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potential functional importance. The non-synonymous SNP e2/G34A (Val12Met) was 
reported to be associated with substrate recognition and/or transport of drugs, 
suggesting that this polymorphism impairs the specific apical membrane localization 
of ABCG2 (Tamura et al. 2006; Tamura et al. 2007). Moreover, Mizuarai et al. (2004) 
have reported that the G34A variant exhibits reduced drug resistance in polarized 
porcine kidney epithelial LLC-PK1 cells along with increased intracellular drug 
accumulation. 
At last, another target SNP within ABCG2 for this study was T-357C that occurs in the 
intron 9 of the gene. Because this SNP is found to change an intronic splice regulatory 
element (ISRE) and mutations in ISREs can alter the pre-mRNA splicing (Yeo et al. 
















Table 4  Frequency of the C421A BCRP allele among different ethnic populations 
 (Yanase et al. 2006) [Reprinted, with permission] 
 
Abbreviations: N, number of patients studied; C/A, heterozygous frequency; A/A, 
homozygous variant frequency; Ref., reference. 
  








  Reference 
  C/A A/A   
Asian (Japanese) 124 48 9 27 Imai et al. 2002 
Asian (Japanese) 120 45 14 30 Kobayashi et al. 2005  
(Han Chinese) 95 43 11 34 de Jong et al. 2004 
Caucasian 150 25 4 11 Kobayashi et al. 2005  
Caucasian 150 22 2 9 Mizuarai et al. 2004 
(American) 88 19 1 12 de Jong et al. 2004 
(European) 84 14 2 11 de Jong et al. 2004 
(Swedish) 60 10 1 10 Backstrom et al. 2003 
African  
(sub-Saharan) 938 14 1 1 de Jong et al. 2004 
African-American 94 8 1 5 de Jong et al. 2004 





     
                  Table 5  Summary of selected target SNPs within four ABC Transporter Genes found to be potentially functional (pages 30-32) 
Gene SNP ID dbSNP (rs) Amino Acid Change Reports on Functionality Reference 
Associate with expression and activity of 
ABCB1 in duodenum 
Hoffmeyer et al. 2000 
Alteration in the rate of translation Kimchi-Sarfaty et al. 2007 
Associate with increased digoxin plasma 
concentrations 
Johne et al. 2002 
Associate with ABCB1 mRNA expression 
levels  in Japanese subjects (TT>CC) 
Nakamura et al. 2002 
Associate with ABCB1 mRNA expression 
levels  in Caucasian subjects 
Siegmund et al. 2002 
Associate with ABCB1 mRNA expression 
levels in liver 
Wang* et al. 2005 
Associate with ABCB1 mRNA expression 
levels in liver 
Song et al. 2006 
Associate with ABCB1 mRNA expression 
levels in kidney 
Haenisch et al. 2007 
Associate with ABCB1 expression levels in 
term placenta 
Tanabe et al. 2001 
e26/C3435T rs1045642 Ile1145Ile 
Associate with ABCB1 expression levels in 
term placenta 
Hitzl et al. 2004 
ABCB1 
e21/G2677T/A rs2032582 Ala893Ser/Thr Associate with ABCB1 mRNA expression levels in liver 
Song et al. 2006 
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Gene SNP ID dbSNP (rs) Amino Acid Change Reports on Functionality Reference 
Associate with ABCB1 mRNA expression 
levels in kidney 
Haenisch et al. 2007 
Associate with ABCB1 mRNA expression 
levels in heart Meissner et al. 2004 
Associate with ABCB1 expression levels in 
term placenta Tanabe et al. 2001 
Associate with ABCB1 expression levels in 
term placenta Hitzl et al. 2004 
e21/G2677T/A rs2032582 Ala893Ser/Thr 
Associate with ABCB1 expression levels in 
term placenta Sherif et al. 2007 
Associate with increased exposure to 
irinotecan in cancer patients Mathijssen et al. 2003 
Associate with ABCB1 expression in 
isogenic fibroblasts Aird et al. 2007 
ABCB1 
e12/C1236T rs1128503 Gly412Gly 
Associate with ABCB1 expression levels in 
breast tumors Vaclavikovaa et al. 2008 
ABCC1 5'FR/G-260C rs504348 -- Affect ABCC1 promoter activity Wang et al. 2005 
A risk factor for the development of spina 
bifida Jensen et al. 2004 
T allele associates with lower mRNA levels 





e1/C-24T rs717620 -- 
Affect ABCC2 promoter activity Wang et al. 2007 
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Gene SNP ID dbSNP (rs) Amino Acid Change Reports on Functionality Reference 





e25/G3542T rs8187692 R1181L Has evidence of recent positive selection Wang et al. 2007 
Associate with ABCG2 protein expression 
and protein structural changes 
Imai et al. 2002  
Mizuarai, et al. 2004 
Morisaki et al. 2005 
Kobayashi et al. 2005 
Kondo et al. 2004 
Has evidence of recent positive selection Wang et al. 2007 
e5/C421A rs2231142 Q141K 
Associate with ABCG2 expression levels in 
term placenta Kobayashi et al. 2005 
Impairs the specific apical membrane 
localization of ABCG2 
Tamura et al. 2006  
Tamura et al. 2007 
e2/G34A rs2231137 Val12Met 
Associate with  drug resistance in polarized 
porcine kidney epithelial LLC-PK1 cells Mizuarai et al. (2004) 
ABCG2 
I9/T-357C rs2054576 -- Change an intronic splice regulatory 
element 










      
 
1.6 Objectives of this study 
 
As discussed, ABCB1, ABCC1, ABCC2, and ABCG2 are highly expressed in tissues 
important for absorption (e.g., lung and gut) and metabolism (liver) and elimination 
(liver and kidney). In addition, these transporters have an important role in barrier site 
tissues (e.g., placenta). Thus, these ABC transporters are capable to modulate the 
absorption, distribution, metabolism, excretion, and toxicity of xenobiotics in maternal 
circulation. Moreover, these transporters are found to be highly expressed in placenta 
and are involved in both materno-fetal and feto-maternal trafficking of exogenous or 
endogenous substances. Therefore, they are actively involved in absorption of 
nutrition by the fetus and modulating the level of toxicants, drugs, and their 
metabolites ingested by the mother in the fetal circulation. It is known that the 
functional sequence variations in these genes might alter the expression or function of 
the transporter proteins.  
The current study aimed to investigate the role of important SNPs within the four 
members of ABC-transporter family in non-syndromic orofacial clefting in which 
disease risk is mediated by environmental toxicants or nutritional insufficiency during 
embryonic life. 
Considering common environmental risk factors for different types of orofacial clefts, 
for the current study the phenotype of interest included all forms of non-syndromic 
orofacial clefts including cleft lip (unilateral or bilateral) with or without cleft palate 
(CL/P), cleft palate (CP), or both. However, the aim of this study was not to 
investigate the role of different environmental factors in the disease risk.  
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1.7 Significance of this study 
 
It is important to acknowledge that in human placenta, the understanding of the 
activity of different ABC transporters is very preliminary. However, the understanding 
of the association of functional sequence variations in ABC genes known to be 
expressed in placenta with birth defects and the interactions of environmental factors 
such as drugs with placental transporters is very important. Because it can provide a 
novel framework for further studies on drug development and the choice of therapy in 
pregnancy in which medications can be designed to control the degree of fetal 
exposure and thus prevent fetal risk. Moreover, it would be helpful to screen 
pregnancies that are in higher risk because of less placental protection on the fetus to 
bring them under close observation especially in case of maternal pharmacotherapy or 
smoking.  
1.8 Study design and Genotyping method 
 
This study designed in two formats of family-based and case-control study. Subjects 
were genotyped for the target genes and SNPs using genomic DNA extracted from 
peripheral blood. Genotyping was accomplished by multiplex PCR amplification, 
multiplex minisequencing and TaqMan® SNP genotyping assay. In addition, DNA 
sequencing as a reliable genotyping method was employed to validate unclear 
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2 MATERIAL AND METHODS 
 
2.1 Protocol of subject recruitment and Sample size  
 
To estimate the number of case-parent trios needed to detect genes exerting modest 
(doubling, r=2) to strong (quadrupling, r=4) levels of relative risks, the Quanto 
program of Guaderman (2002) was used.  Table 5 shows the number of trios needed to 
attain 80% power under different risk models, assuming risk allele frequencies (pA) of 
0.01, 0.1, 0.25, and 0.5.  A sample size of ~150 trios will be adequate to detect 
common genes with moderate (r=2) or large effect (e.g. r=4) when the risk allele 
frequency (pA) is 0.1 or higher, assuming a dominant or codominant (i.e. log-additive) 
genetic model.  However, this sample size will be inadequate for risk alleles with a 
recessive genotypic effect, for which larger sample sizes will be required. 
 
Thus, for the study a population of 150 nuclear families with single oral cleft child 
was recruited through treatment centers in Singapore and Taiwan with prior approval 
from the Institutional Review Boards (IRB) in both countries. In the families, the 
parents were all unaffected with oral clefts and the ethnicity of the population study 
consisted of Chinese (128 families), Malays (10 families), Indians (4 families) and 
Table 6 Number of parent-child trios needed to achieve 80% power in the TDT with single 
affected offspring families. 
pA 0.01 0.1 0.25 0.5 
Genetic model r=2 r=4 r=2 r=4 r=2  r=4 r=2 r=4 
Log-Additive (r12=r1=r) 1178 212 141 29 77 19 69 20 
Dominant (r2=r1=r) 1205 221 175 41 127 36 189 63 
Recessive (r2=r, r1=1) 146146 24317 1587 271 309 58 129 31 
pA: frequency of risk allele A at SNP locus 
r: genotypic relative risk; r1: relative risk of genotype Aa; r2: relative risk of genotype AA 
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other ethnicities (8 families). However, the family based studies are robust against 
differences exist in ethnicities and genetic background.  
For the case-control study, two groups of cases separately were compared against a 
group of unrelated controls. The population of controls consisted of cord blood DNA 
samples obtained from 189 healthy Chinese mothers. Case group once consisted of 
129 Chinese mothers of oral cleft children, and another time cases were 128 Chinese 
oral cleft children recruited for the family based study. The ethnicities were all 
determined through case files and hospital records.  
 
2.2 Laboratory Methods  
 
2.2.1 PCR and Minisequencing   
 
A single triplex PCR was designed to amplify the fragments of ABCB1, ABCC1, and 
ABCG2 containing the three SNPs 2677G>T/A, 5'FR/G-260C, and 34G>A, 
respectively. Moreover, multiplex minisequencing was optimized for genotyping the 
PCR products at the interested loci. The Operon online software was applied to design 
primers for both PCR and minisequencing experiments. Information on the designed 
primers as well as the reaction conditions have been tabulated in Table 7.  
Briefly, for the triplex PCR, a 10 µL reaction mixture was prepared containing PCR 
buffer (Qiagen), 1.5 mM MgCl2, 200 µM each of the four deoxynucleotide 
triphosphates (dNTPs), 1 U of HotStarTaq® Polymerase (Qiagen), and 0.5 ng of 
template DNA. The final primer concentrations (Table 7A) were 0.2 µM (for 
ABCB1/exon 21), 0.4 µM (for ABCG2/exon 2), and 0.5 µM (for ABCC1/5'FR). The 
reaction mixture was subjected to initial denaturation at 95 °C for 15 min followed by 
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35 step-cycles of denaturation at 94 °C for 1 min, annealing at 55 °C for 30 s, and 
extension at 72 °C for 1 min. This was followed by a final extension at 72 °C for 5 
min. All PCR amplifications carried out in 96-well plates using T1 thermal cycler 
(Biometra). The expected PCR fragments and their sizes are shown in Table 7A. After 
PCR amplification, unincorporated dNTPs and excess primers were inactivated and 
degraded in a single-step reaction by addition of 5 U of exonuclease I and 0.5 U of 
shrimp alkaline phosphatase (SAP; United States Biochemical), respectively, to 1.3 
µL of the PCR product in a final volume of 2 µL. Then, the reaction mixture was 
incubated at 37 °C for 1h, and the enzymes were subsequently inactivated at 80 °C for 
15 min. The treated PCR products were then subjected to a multiplex minisequencing 
reaction to interrogate the three SNP loci simultaneously.  
Minisequencing primers were designed to anneal to template DNA next to each SNP 
site such that extension by DNA polymerase added a single dideoxyribonucleoside 
triphosphate (ddNTP) complementary to the nucleotide at the polymorphic site. Table 
7B details the sequences of the minisequencing primers and their concentrations in the 
final minisequencing reaction mixture. The multiplex minisequencing reaction 
contained the treated triplex PCR product (1.5 µL), various concentrations of 
minisequencing primers, and 1 µL of SNaPshotTM Multiplex Ready Reaction Mix 
(Applied Biosystems) in a total reaction volume of 4 µL. The reaction mixture was 
then subjected to 25 single-base extension cycles of denaturation at 96 °C for 10 s, 
primer annealing at 50 °C for 5 s, and primer extension at 60°C for 30 s. Thereafter, 
unincorporated fluorescent ddNTPs were inactivated enzymatically with 0.5 U of SAP 
at 37 °C for 30 min, followed by SAP deactivation at 80 °C for 15 min. The multiplex 
minisequencing products (0.8 µL) were then mixed with 9 µL of HiDiTM formamide 
and 0.1 µL of GeneScan-120 LIZ size standard (Applied Biosystems), and resolved by 
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automated capillary electrophoresis for 25 min on an ABI PRISM 3100® AVANT 
Genetic Analyzer (Applied Biosystems, Foster City, CA).  
Minisequencing analyses were performed with the GeneScan (V3.7) application 
software (Applied Biosystems). Samples that did not give a reliable result in the first 
round of genotyping were resubmitted to up to two additional rounds of genotyping 
and DNA sequencing was performed whenever the minisequencing was unsuccessful.
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Table 7  Multiplex PCR and minisequencing of the ABCB1, ABCC1, and ABCG2 genes. 
 
A. Primers for the triplex PCR of the 3 genomic regions of the ABCB1, ABCC1, and ABCG2 genes                                                                                                
 Gene Amplified Region 5'-Primer 3'-Primer Conc. 
(µM) 
Amplicon Length (bp)   
ABCB1 Exon 21 5'-ATAGCAAATCTTGGGACAGG-3' 5'-GCATAGTAAGCAGTAGGGAG-3' 0.2 256 
ABCC1 Promoter  5'-CAGGATGAAATGAGGGCACAG-3' 5'-GAAGCGCCTGGGATCTTTGG-3' 0.5 155 
ABCG2 Exon 2 5'-GTTCATAGCCAGTTTCTTGG-3' 5'-GTTCTTATCACAATGGTATGG-3'   0.4 466 
                   
B. Primers for the triplex minisequencing of the 3 SNPs within ABCB1, ABCC1, and ABCG2 genes  
Nucleotide Sequence 
* Gene 
* SNP ID 
* dbSNP (rs) 
Location Region 




















ABCB1   
2677G>T/A 
rs2032582 
Exon 21 TM- 9.10 gaaggtGctggga 
gaaggtTctggga 
gaaggtActggga 
Reverse  5'-T(GACT)2TAGTTTGACTCACCTTCCCAG-3' 30 0.26 
ABCC1                
5'FR/-260G>C 
rs504348 
5'FR Promoter aaacagGatttga aaacagCatttga Reverse 5'-CCTGCGACCACTTTTCAAAT-3' 20 0.52 
ABCG2 34G>A 
rs2231137 
Exon 2 - gtgacaGtgggat gtgacaAtgggat Reverse 5'-(GACT)GGTAATGTCGAAGTTTTTATCCCA-3' 28 0.13 
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2.2.2 TaqMan® SNP Genotyping Assays (Applied Biosystems) 
 
The TaqMan assay (Applied Biosystems) was accomplished for SNP analysis in 
ABCB1, ABCC2, and ABCG2 using original DNA samples. Table 8 displays the 
TaqMan Assay ID for the selected target SNPs within theses genes.  
      
Table 8  Target SNPs for TaqMan Assay 
Gene SNP ID dbSNP (rs) TaqMan Assay SNP ID 
e12/C1236T rs1128503 C-7586662-10 
ABCB1 
e26/C3435T rs1045642 C-7586657-1 
e1/G-24A rs717620 C-2814642-10 
e10/G1249A rs2273697 C-22272980-20 ABCC2 
e25/G3542T rs8187692 C-25591748-30 
e5/C421A rs2231142 C-15854163-70 
ABCG2 
I9/-357T>C rs2054576 C-11945745-10 
 
The assay was carried out in a volume of 5 µL containing 1X TaqMan Universal PCR 
Master Mix, 1X SNP Genotyping Assay Mix (primers and fluorescent probes), and 
1ng genomic DNA. The reaction mixture was subjected to initial AmpliTaq Gold 
Enzyme Activation at 95 °C for 10 min followed by 40 step-cycles of denaturation at 
92 °C for 15 s, and thannealing at 60 °C for 1 min using T1 thermal cycler (Biometra) 
for 96-well plates. 
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Plate read after PCR amplification was performed on the Applied Biosystems 7500 
Real-Time PCR System and SDS v1.4 software was used to determine allelic 
discrimination during a postamplification plate read based on Rn values (the ratio of 
fluorescence) of the signals from each well.  
2.2.3 PCR and DNA Sequencing 
 
Whenever the results of the SNP genotyping by minisequencing or TaqMan assays 
were not clear enough, genotyping was repeated by sequencing the PCR product of 
the DNA fragment containing the respective SNP in the forward or reverse direction 
using the same PCR primers. 
Unless for a few samples, the TaqMan SNP genotyping assay for ABCC2 SNP 
G1249A was unsuccessful to clearly determine the SNP genotype. Hence, DNA 
sequencing was performed for samples that the TaqMan assay results was unreliable 
as follows:   
First, the PCR reaction was performed in a 10 µL volume reaction containing 1 ng 
genomic DNA template, 5 µL 2X PCR master mix buffer (Qiagen, Valencia, CA, 
USA), 0.5 µM forward primer (5'-GAGCACATCCTTCCATTGTAATC-3'), and 0.5 
µM reverse primer (5'-ACTGAGGGTCCCAACTCTCTC-3'). The thermal cycling 
conditions for PCR using a T3 thermal cycler (Biometra) was as follows: Initial 
activation at 95 oC for 15 min followed by 35 cycles of denaturation at 95 for 30 s, 
primer annealing at 62 °C for 30 s, and primer extension at 72 °C for 30 s. This was 
then followed by a final elongation step at 72 oC for 5 min.  
Thereafter, the obtained amplification products (281 bp) were treated with 
exonuclease I and shrimp alkaline phosphatase (SAP, United States Biochemical). 
Then a 10 µL sequencing reaction mixture using ABI PRISM Big Dye (V3.1) kit was 
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prepared containing 2.5 µL 1X Sequencing Buffer, 0.5 µL BigDye (V3.1), 0.16 µM of 
the reveres primer used in the PCR reaction, and the treated PCR product.  
Thermal cycling conditions for the above reaction was 94 oC for 15 min followed by 
30 cycles at 96 oC for 10 sec, 50 oC for 5 sec and 60 oC for 4 min. Thereafter, DNA 
precipitation was performed with EDTA and Ethanol and the final product was 
resolved by automated capillary electrophoresis on an ABI PRISM 3100® AVANT at 
94 for 30 s, primer annealing at 60 °C for 30 s, and primer extension at 72 °C for 30 s. 
This was then followed by a final elongation step at 72 oC for 5 min. Genetic Analyzer 
(Applied Biosystems, Foster City, CA). The GeneScan (V3.7) application software 
(Applied Biosystems) was applied to read and analyses the data. 
To validate the TaqMan assay results for another ABCC2 SNP in exon 25 (G3542T), 
PCR amplification and sequencing was carried out as follows: 
The PCR reaction was prepared in a 10 µL volume reaction containing 1 ng genomic 
DNA template, 5 µL 2X PCR master mix buffer (Qiagen, Valencia, CA, USA), 0.4 
µM forward primer  (5'-ACTCTGTCACCAGGTCCC-3'), and 0.4 µM reverse primer 
(5'-CCTCCCACCGCTAATATC-3'). The reaction mixture was subjected to initial 
activation at 95 oC for 15 min followed by 35 cycles of denaturation. Thereafter, 
sequencing of the PCR product was performed using ABI PRISM BigDye (V3.1) kit 
and 0.16 µM of the PCR forward primer. All PCR amplifications and sequencing 
reactions were carried out using T3 thermal cycler (Biometra).  
In addition, PCR and sequencing were used to verify the minisequencing results for 
the SNPs 2677G>T/A of ABCB1 and G34A of ABCG2 whenever the TaqMan 
genotyping results were unclear. In order for the SNP 2677G>T/A, ABI PRISM 
BigDye (V3.1) sequencing kit and 0.16 µM of the reverse PCR primer and for the 
CHAPTER 2 
 
                                                                                
 
   44                                      
SNP G34A, the same sequencing kit but 0.16 µM of the forward PCR primer were 
used.   
2.3 Statistical analysis methods 
 
2.3.1 Family-based study 
 
The genotype data of the one hundred and fifty complete trios of non-syndromic oral 
cleft patients and their biological parents were assessed for the Mendelian consistency 
within each family as well as for deviations from Hardy-Weinberg equilibrium (HWE) 
to ascertain the data are reliable and error free. An online calculator 
[http://www.husdyr.kvl.dk/htm/kc/popgen/genetik/applets/kitest.htm] was used for the 
HWE analysis. Thereafter, the transmission disequilibrium test (TDT) on the diallelic 
SNPs and extended transmission disequilibrium test (ETDT) on the tri-allelic SNP 
2677 of ABCB1 were performed using ETDT software developed by Sham and Curtis 
(1995). The odds ratios as well as 95% confidence intervals were also computed with 
an online calculator [http://www.graphpad.com/quickcalcs/McNemar1.cfm].  
2.3.2 Case-control study 
 
The online calculator [http://www.husdyr.kvl.dk/htm/kc/popgen/genetik/applets/kitest.htm] 
was applied to evaluate the significance of deviation of each SNP in the study 
populations from Hardy-Weinberg Equilibrium (HWE). Thereafter, pair-wise 
comparisons of alleles frequency between two different groups of cases and controls 
were performed using Fisher’s exact test and Chi-squared (df = 2) for the diallelic 
SNPs and the ABCB1 tri-allelic SNP 2677, respectively. Moreover, an online program 
[http://faculty.vassar.edu/lowry/odds2x2.html] was employed to compute the odds 
ratios and corresponding 95% confidence intervals for each examined SNP.  
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2.3.3 Integrating TDT and Case-control studies 
To obtain a combine estimate for the disease-SNP association from both family based 
and case-control studies, a joint analysis was performed with the analytical method 
introduced by Kazeem and Farrall (2005).  
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3 RESULTS AND DISCUSSION  
 
3.1 Laboratory Results 
 
The results of multiplex PCR and minisequencing optimized for simultaneous 
genotyping of three SNPs G-260C, G34A, and G2677T/A is illustrated in Figure  3-1.  
A  
 
             B                              ABCC1: -260      ABCG2: 34  ABCB1: 2677 
 
Figure  3-1  Multiplex PCR and genotyping results for the three ABC genes SNPs. 
(A), Agarose gel electrophoresis of the multiplex PCR products from five representative 
samples. A 2-µL aliquot of each reaction product was resolved on a 1.5% agarose gel. (B), 
GeneScan 3.7 analysis of multiplex-minisequencing products. Electropherograms of 
representative samples with different genotypes at the three SNP sites are shown. Each SNP 
allele displays a characteristic peak color, position, and height relative to the other allele peak. 
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The genotyping results of the ABCC2 SNP in exon 25 (G3542T) for all samples 
displayed a pattern of monomorphism, therefore this SNP was excluded from further 
evaluation and the study was limited to the analysis of the rest 9 SNPs in the families, 
cases and controls . 
3.1.1 Results of TDT-McNemar analysis on nuclear families 
 
In parents and probands, the genotyping distributions were all in Hardy-Weinberg 
equilibrium and no statistically significant deviation was found (P>0.05) [Table 11]. 
Strikingly, the TDT-McNemar analysis revealed that the SNPs within the ABCB1 
gene (e12/1236, e21/2677, and e26/3435), but not SNPs in other ABC genes were 
significantly associated with orofacial clefting (P<0.05). However, after Bonferroni 
correction, only SNP e12/1236 (rs1128503) remained significantly associated (P = 
0.000051) with the oral clefts in the family samples while the two SNPs e21/2677, and 
e26/3435 showed a nominal association (Table 12).  
Further allelic-wise analysis using modified McNemar’s test showed a preferential 
transmission of the variant alleles (T) compared to the wild type alleles (C) in the 
SNPs 12/1236 (C>T) and e26/3435 (C>T). Similarly, as to the tri-allelic ABCB1 SNP 
e21/2677(G>T,A), a chi-square statistic (df =1) could show a preferential transmission 
for the T and A alleles compared to the G allele from heterozygote parents to the 
probands. However, after correction for multiple testing only the P-value for the T 
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Table 9  Transmission for individual alleles of SNP e21/2677 (G>T, A) 
 
 
*Because the expected number of times for each allele to be passed and not passed to 
the probands is half the total number of times a heterozygote parent has the allele, the 
expected values calculated accordingly.   
 
A novel analysis method was designed to evaluate the role of the maternal genotype 
for the target SNPs in vulnerability to orofacial clefting in addition to the fetal 
genotype. For this analysis, only the oral clefts’ families that both parents were 
Chinese were employed to eliminate the effect of ethnicity and genetic background on 
the genotype distributions. Then, the proportions of homozygote parents (whether 
father or mother) for an SNP allele whose oral cleft child was also homozygote for 
that allele was computed from the genotype data (Table 10). It is plausible that in a 
normal situation a homozygote child for a specific SNP allele has an equal chance for 
having a homozygote father or a homozygote mother for that SNP allele. Thus, if the 
frequency of families with a homozygote oral cleft child for a particular variant SNP 
allele whose mother is also homozygote for the same allele is significantly greater 
ABCB1 SNP e21/2677  
Allele A G T 
Number of times passed 23 78 96 
Expected number of times passed* 32.5 84.5 80 
Number of times not passed 42 91 64 
Expected number of times not passed* 32.5 84.5 80 
Chi-squared 5.554 1.000 6.400 
P-value of chi-squared test (df=1) 0.0185 0.3174 0.0114 
Corrected P-value for multiple testing 0.0555 0.9522 0.0342 
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than the frequency of families with a homozygote father and child for that SNP allele, 
it can favor the synergistic effect of the maternal genotype in the disease risk.  
As shown in Table 10,  a Two Dependent Proportions Testing using an online 
calculator [http://home.ubalt.edu/ntsbarsh/Business-stat/otherapplets/PairedProp.htm] 
revealed no significant difference between the frequencies of homozygote father/child 




Table 10  Proportions of genotype distributions in 129 Chinese families of oral cleft patients   
when both mother and her child or both father and his child were homozygote for wild type 
and mutant SNP alleles  
 
Polymorphism Child/Parent Genotype 
Homozygote  
child and mother 
proportions  
Homozygote  
child and father 
proportions 




TT/TT 0.290 0.290 - rs1128503 
(e12/C1236T) CC/CC 0.039 0.031 0.366 
TT/TT 0.047 0.054 0.402 
AA/AA 0.000 0.000 - rs2032582  (e21/G2677T/A) GG/GG 0.085 0.093 0.415 
CC/CC 0.302 0.225 0.114 rs1045642 
(e26/C3435T) TT/TT 0.047 0.054 0.402 
GG/GG 0.969 0.977 0.474 rs504348 
(5'FR/G-260C) CC/CC 0.000 0.000 - 
CC/CC 0.504 0.473 0.361 rs717620 
(e1/C-24T) TT/TT 0.007 0.000 0.171 
GG/GG 0.760 0.705 0.303 rs2273697 
(e10/G1249A) AA/AA 0.000 0.000 - 
CC/CC 0.333 0.326 0.461 rs2231142 
(e5/C421A) AA/AA 0.023 0.031 0.348 
GG/GG 0.287 0.310 0.368 rs2231137 
(e2/G34A) AA/AA 0.023 0.047 0.152 
TT/TT 0.419 0.395 0.382 rs2054576  
(I9/T-357C) CC/CC 0.016 0.023 0.344 
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Table 11  Genotype and allele frequencies of the polymorphisms in oral cleft patients and biological parents 
 
                               
Polymorphism  No Genotype     HWE (p) Allele frequencies 
rs1128503   T                C 
Parents 300 0.90 0.642        0.358 
Probands 150 
 TT          TC          CC                            
124         137           39                                                                                        
79            58            13 0.62 0.720        0.280 
rs2032582     A                G               T 
Parents 300 0.13 0.118        0.488         0.393 
Probands 150 
AA         AG          AT         GG          GT          TT              
3              37            28           62           132           38       
0              16            10           32             60           32 0.42 0.087        0.467         0.447  
rs1045642   CC         CT           TT  C                T 
Parents 300  120         143            37 0.57 0.638         0.362 
Probands 150                           55           66            29 0.25 0.587         0.413 
rs504348   GG         GC          CC  G                C 
Parents 300  293             7             0 0.84 0.988         0.012 
Probands 150  146             4             0 0.87 0.987         0.013 
rs717620   TT          TC           CC  T                C 
Parents 300    15           91           194 0.32 0.202         0.798 
Probands 150     5           55             90 0.33 0.217         0.783 
rs2273697   AA         AG           GG  A                G 
Parents 300      4           56            240 0.72 0.107         0.893 
Probands 150      1           24            125 0.89 0.087         0.913 
rs2231142  AA         AC           CC  A                C 
Parents 300    20          132           148 0.19 0.287         0.713 
Probands 150    13           56              81 0.46 0.273         0.727 
rs2231137  AA          AG          GG  A                G 
Parents 300   33           125          142 0.49 0.318         0.681 
Probands 150   16             72            62 0.47 0.347         0.653 
rs2054576  CC          CT           TT  C                T 
Parents 300   17           110          173 0.93 0.240         0.760 
Probands 150     9             50            91 0.36 0.227         0.773 
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         Table 12  Transmission disequilibrium test in oral clefts cases 
                                                 
                                                                         
                                                                   
n1: Number of family 
samples which were 
successfully genotyped. 
n2: Number families with 
at least one heterozygote 
parent.                                                           
T: Transmitted          
NT: non-transmitted          
Gene/Marker Marker Allele n1 n2 T/NT 
P-value for 
allele-wise TDT Odds ratio 95% CI 
ABCB1: 12/1236 
(rs1128503) 
T>C 150 108 T: 92/45             
C: 45/92 
0.000051 2.044 1.416 - 2.989 
ABCB1: 21/2677 
(rs2032582) 
G>T, A 150 111 G: 78/91            
T: 96/64               
A: 23/42 
0.008592 1.500     
(For T allele) 
1.082 - 2.091 
ABCB1: 26/3435 
(rs1045642) 
C>T 150 110 C: 56/87             
T: 87/56 
0.009277 1.554 1.098 - 2.214 
ABCC1: 5'FR/-260 
(rs504348) 
G>C 150     7 G: 3/4                
C: 4/3 
0.704992 1.333 0.226 - 9.102 
ABCC2: e1/-24 
(rs717620) 
C>T 150   76 C: 41/50             
T: 50/41 
0.345100 1.244 0.808 - 1.925 
ABCC2: e10/1249 
(rs2273697) 
G>A 150   53 G: 34/22            
A: 22/34 
0.107503 1.545 0.878 - 2.774 
ABCG2: e5/421 
(rs2231142) 
C>A 150 110 C: 70/62            
A: 62/70 
0.486130 1.129 0.791 - 1.616 
ABCG2:  e2/34             
(rs2231137) 
G>A 150 105 G: 54/71 
A: 71/54 
0.127852 1.315 0.910 - 1.909 
ABCG2: I9/-357 
(rs2054576) 
T>C 150   91 T: 59/51             
C: 51/59 
0.445434 1.157 0.782 - 1.717 
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3.1.2 Statistical analysis on the genotype data of cases and controls 
 
 
The genotype distribution of all polymorphisms investigated was in Hardy-Weinberg 
equilibrium (χ2<3.84, P>0.05) in oral cleft cases, their mothers and controls.  
Results of the Fisher’s exact test and the Chi-square analysis revealed no significant 
differences in the alleles’ frequency of the target SNPs between Chinese mothers of 
oral cleft children and the controls (Table 13). However, in another comparison 
between the Chinese oral cleft cases and the controls, interestingly a significant 
difference revealed in the alleles’ frequency of the ABCB1 SNP e12/1236 (rs1128503) 
(OR = 1.60, P = 0.0046) and it was remained significant even after Bonferroni 
correction for multiple testing. In this analysis, no significant differences found in the 
alleles’ frequencies of other examined SNPs between the cases and controls. The 
results are given in details in Table 14.  
In line with HapMap reports, the ABCC1 SNP at position 5'FR/G-260C exhibited very 
low minor allele frequency in our samples; however, this SNP was genotyped to test 
for penetration.  
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Table 13  Genotype and allele frequencies of SNPs and association analysis of each SNP in controls and mothers of oral cleft children 
Polymorphism  No Genotype HWE (p) Allele frequencies 
P-value for allele-
wise Fisher's exact/ 
Chi-square test 
OR 95% CI 
rs1128503  TT             TC            CC        T                                         C 
Controls 189   78              80               31 0.18 236 (0.624)                        142 (0.376)           
Mothers 129   53              58               18 0.74 164 (0.636)                          94 (0.364) 
0.4186 0.95 0.69 - 1.32 
rs2032582   AA    AG    AT    GG     GT     TT        A                   G                  T 
Controls 189     2       25     11      42      72       37                    0.22 40 (0.106)    181 (0.479)    157 (0.415) 
Mothers 129     2       20       9      33      50       15 0.72 33 (0.128)    136 (0.527)      89 (0.345) 
0.1889 1.35 0.05 - 7.38 
rs1045642  CC            CT             TT        C                                        T 
Controls 189  71              86               32 0.46 228 (0.603)                        150 (0.397) 
Mothers 129  61              53               15 0.51 175 (0.678)                          83 (0.321) 
0.0321 1.39 0.99 - 1.93 
rs504348  GG            GC            CC        G                                        C 
Controls 189         186                3               0 0.91 375 (0.992)                            3 (0.008) 
Mothers 129         128                1               0 0.97 257 (0.996)                            1 (0.004) 
0.4651 0.49 0.05 - 4.70 
rs717620  TT             TC            CC        T                                        C 
Controls 189    6              52             131 0.76   64 (0.169)                        314 (0.831) 
Mothers 129   7              38               84 0.36 52 (0.202)                        206 (0.798) 
0.1763 0.81 0.54 - 1.21 
rs2273697  AA            AG            GG        A                                        G 
Controls 189    0              36             153 0.15   36 (0.095)                        342 (0.905) 
Mothers 129    0              19             110 0.37 19 (0.074)                        239 (0.926) 
0.2105 1.32 0.74 - 2.36 
rs2231142  AA            AC             CC        A                                        C 
Controls 189  11              83               95 0.19 105 (0.278)                        273 (0.722) 
Mothers 129  11              50               68 0.68 72 (0.279)                        186 (0.721) 
0.5207 0.99 0.70 - 1.41 
rs2231137  AA            AG             GG        A                                        G 
Controls 189  18              92               79  0.23 128 (0.339)                        250 (0.661) 
Mothers 129  15              60               54 0.79   90 (0.349)                        168 (0.651) 
0.4274 0.96 0.69 - 1.33 
rs2054576          CC            CT              TT        C                                        T 
Controls 189            6              68             115 1.16   80 (0.212)                        298 (0.788) 
Mothers 129          10              44               75 0.95   64 (0.248)                        194 (0.752) 
0.1632 1.23 0.84 - 1.79 
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 Table 14  Genotype and allele frequencies of SNPs and association analysis of each SNP in controls and oral cleft sample 
Polymorphism No Genotype   HWE (p) Allele frequencies 
P-value for allele-
wise Fisher's exact/ 
Chi-square test 
OR 95% CI 
rs1128503  TT          TC         CC          T                                       C 
Controls 189  78           80            31 0.18 236 (0.624)                        142 (0.376)           
Oral clefts 128  68           50            10 0.85 186 (0.727)                          70 (0.273)                 
0.0046   1.60 1.13 - 2.26 
rs2032582   AA    AG    AT     GG      GT    TT          A                  G                  T 
Controls 189     2      25      11       42        72     37                    0.22 40 (0.106)    181 (0.479)   157 (0.415) 
Oral clefts 128     0      15       9        28        51     25 0.46 24 (0.094)    122 (0.477)   110 (0.430) 
0.8622 0.94 0.05 - 7.38 
rs1045642  CC         CT          TT          C                                       T 
Controls 189  71          86            32 0.46 228 (0.603)                        150 (0.397) 
Oral clefts 128  49          55            24 0.23 153 (0.598)                        103 (0.402) 
0.4770 0.98 0.70 - 1.35 
rs504348  GG         GC         CC          G                                       C 
Controls 189 186            3             0 0.91 375 (0.992)                            3 (0.008) 
Oral clefts 128 126            2             0 0.93 254 (0.992)                            2 (0.008) 
0.6765 1.016 0.17 - 6.12 
rs717620  TT         TC          CC          T                                        C 
Controls 189    6          52           131 0.76   64 (0.169)                        314 (0.831) 
Oral clefts 128   3          48            77 0.15   54 (0.210)                        202 (0.789) 
0.1121 1.31 1.31 - 0.88 
rs2273697  AA         AG         GG          A                                       G 
Controls 189    0          36           153 0.15   36 (0.095)                        342 (0.905) 
Oral clefts 128    1          20           107 0.95   22 (0.086)                        234 (0.914) 
0.4009 0.89 0.51 - 1.56 
rs2231142  AA         AC          CC          A                                       C 
Controls 189  11           83            95 0.19 105 (0.278)                        273 (0.722) 
Oral clefts 128  13           50            65 0.47   76 (0.297)                        180 (0.703) 
0.3319 1.01 0.77 - 1.56 
rs2231137  AA        AG          GG          A                                       G 
Controls 189  18           92            79 0.23 128 (0.339)                        250 (0.661) 
Oral clefts 128  14           58            56 0.86   86 (0.336)                        170 (0.664) 
0.5069 0.99 0.71 - 1.38 
rs2054576             CC         CT           TT          C                                        T 
Controls 189 
              6           68           115 1.16   80 (0.212)                        298 (0.788) 
Oral clefts 128               9           46             73   0.64   64 (0.250)                        192 (0.750) 
0.1505 1.24 0.85 - 1.81 
                                                                                 
 
55 
3.1.3  Joint analysis of TDT and Case-control results 
 
Table 15 details the results of a joint analysis on the TDT and case-control results for 
the ABCB1 SNP e12/1236 that found to be significantly associated with non-
syndromic oral clefts in the family and the case-control based studies.  
The analysis disclosed that the odds ratios were homogenous in the two family based 
and case-control studies (P*>0.05) and the estimate of the combined odds ratio was 
calculated by 1.79, which was highly significant (P-value <0.0001).  
 
Table 15  The results of joint analysis of the TDT and case-control studies 
 Case-Control study TDT study Combined results 






1.58   1.12 - 2.23 2.04 1.42 - 2.99 1.79 1.38 - 2.30 <0.0001  0.32 
 





The effect of most teratogens on fetal development is dependent on the fetal exposure. 
Therefore, during fetal development modulation of maternal exposure to 
environmental factors as well as the modulation of fetal exposure to the potentially 
toxic xenobiotics digested by the mother is vital. As ABC transporter proteins are 
thought to be involved in such modulation, this study aimed to investigate the 
association of nine potentially functional SNPs within the four  ABC transporter genes 
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known to be expressed in maternal barrier organs, such as intestine, kidney, liver, 
lung, and the fetal barrier organ i.e. placenta with non-syndromic oral clefts.  
To best of our knowledge there is no evidence to support that a spontaneous mutation 
in these human genes can increase the risk of orofacial clefting as previously 
demonstrated in mice by Lankas et al. (1998). The current study was among the first 
to examine several major ABC genes polymorphisms in children born with orofacial 
clefts. 
Our present study of 150 nuclear families showed that the ABCB1 SNPs e12/1236 is 
significantly associated with non-syndromic oral clefts and the two other ABCB1 
SNPs e21/2677 and e26/3435 have a nominal association. Interestingly, this finding 
was validated by the case-control study of the oral clefts children despite the fact that 
the power of our case-control study is estimated to be less than 50% for SNP e12/1236 
and the sample size used. Moreover, the joint analysis on the family based and case-
control studies could contrast the results of the two studies and revealed that there is 
homogeneity in the strength of the association found.  
One might envision a number of possible explanations for the observed association. 
Nonetheless, to have a better explanation, additional analysis was performed on 
distribution of homozygosity for the target SNPs alleles in Chinese oral cleft families 
(Table 10), which  showed the maternal genotypes had no synergistic effect when both 
mother and child were homozygote for the mutant SNPs alleles. This was further 
confirmed when genotypes and alleles frequencies of the target SNPs compared 
between the Chinese mothers of oral cleft children against controls that showed no 
significant difference between the two groups. This could support the hypothesis that 
the ABCB1 genotype of the fetus and not the mother is a critical factor in determining 
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the disease risk. On the other hand, in case of less ABCB1/P-gp expression in the 
maternal barrier organs, the placental ABCB1 whose expression is influenced by the 
fetal genotype can serve a compensatory role in protecting the fetus from potentially 
toxicants passed the maternal barriers. In contrast, fetal ABCB1 polymorphisms may 
increase the risk of orofacial clefting by altering the P-gp expression or activity in the 
placenta.  
The obtained results suggest that the ABCB1 SNPs e21/2677 and e26/3435 in the 
absence of multiple test correction (MTC) and the SNP e12/1236 even after MTC can 
mediate the diseases risk. As discussed in chapter one, previous studies have revealed 
the functionality of the SNP e12/1236 in various cells but not yet in the placenta. 
However, the studies have disclosed the effect of ABCB1 polymorphisms at e21/2677 
and e26/3435 on P-gp expression in term placentas. Given the placental P-gp 
expression tends to decrease in late pregnancy, it may be necessary to do further 
evaluation in preterm along with the term placentas to clarify the influence of the SNP 
C1236T on P-gp expression/activity in this organ. The SNP C1236T is a non-
synonymous SNP, but Aird et al. (2007) have showed in 3T3 isogenic fibroblasts, 
mutation at position 1236 can significantly alter ABCB1 expression, regardless of 
additional mutations at positions 2677 and 3435.  
Additionally, the allelic-wise analysis in our family based and case-control study 
disclosed a preferential transmission for the T allele of this SNP compared to the C 
allele. This was in line with the report of Vaclavikovaa et al. (2008) that the T variant 
of the SNP C1236T can significantly alter ABCB1 expression in breast tumors. 
Assuming the SNP e12/1236T can result in less P-gp expression in early placenta at 
the time of lip and palate formation, the association found for this polymorphism 
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favors the hypothesis that fetal genotypes harboring the T allele of the SNP C1236T 
might be more vulnerable to orofacial clefts especially in case of maternal smoking or 
pharmacotherapy. It is also possible that the SNP C1236T is not a causal 
polymorphism but is merely in strong linkage disequilibrium with an unobserved 
causal SNP.  
The allelic-wise SNP analysis also revealed that the T allele of SNP 2677 has 
significantly higher transmission to the oral cleft probands over the A and G alleles, 
although the A allele also showed a higher transmission over the wild type G allele in 
the absence of Bonferroni correction. Moreover, the T allele of SNP 3435 was found 
to have higher transmission to the affected offsprings over the C allele. This findings 
are  consistent with the previous studies in term placentas that reported the ABCB1 
SNPs 2677T/A and 3435T were found to be associated with less placental P-gp 
expression (Tanabe et al. 2001; Hitzl et al. 2004; Sherif et al 2007). As discussed in 
chapter one, studies on kidney and heart tissues have reported higher level of ABCB1 
mRNA expression for the carries of T and A alleles of SNP 2677 compared to the G 
carriers. However, the regulation of P-gp expression may significantly differ from 
tissue to tissue, explaining the conflicting reports for the placenta. Moreover, linkage 
studies in Chinese, Malays, and Indians have disclosed that the T alleles of three SNPs 
e12/1236, e26/3435, e21/2677 are frequently linked together. Thus, the observed 
preference in transmission of the T alleles of SNPs 3435 and 2677 might be due to 
their linkage to the SNP 1236T that found to be significantly associated with oral 
clefting.  
Taken together, further studies need to clarify whether fetal ABCB1 genetics 
determines the risk of orofacial malformations in maternal smoking and after 
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unintended or intended maternal drug treatment. It is known that the ABCB1 
expression could be related to both genetic polymorphism and environmental factors, 
such as drugs and smoking. However, in an experiment by Kolwankar et al. (2005) no 
significant difference was found in placental P-gp activity or expression between 
smokers and nonsmokers. Thus, in the current discussion, the genetic polymorphism 
was considered as the main determinant factor for P-gp expression in placenta 
regardless of maternal history for smoking and drug treatment in pregnancy.  
However, it is still possible that in spite of a wild type ABCB1 genotype and high level 
of placental P-gp expression, fetus exposes to potentially toxic xenobiotics. Because 
the concurrent exposure to multiple Pg-p substrates or substrates that are Pg-p 
inhibitor can also impair the placental P-gp activity and increase the disease risk. A 
limitation of our study was the fact that we were not able to study the relationship 
between the ABCB1 gene polymorphisms and maternal histories of smoking and 
pharmacotherapy during pregnancy for the mothers participated in the study. 
Therefore, it remains open whether the findings of this study really reflect the role of 
the placental ABCB1 polymorphisms in increasing the risk of orofacial clefting.  
As discussed in chapter one, ABCB1 in the early stage of gestation, but in late 
gestation ABCC1 and ABCC2 and in mid gestation ABCG2 were found to be highly 
expressed in placenta. Given that the formation of lip and palate completes by the first 
trimester of pregnancy, the role of placental ABCB1/P-gp seems to be more crucial 
than the mentioned ABC transporters in giving protection to the fetus against harmful 
environmental factors. Consistent with this issue in this study, ABCC1, ABCC2 and 
ABCG2 polymorphisms found not to be associated with oral clefting (P>0.05). 
However, it should be confirmed through a study with larger sample size or in 
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ethnicities, which exhibit higher minor allele frequency (MAF) for the examined 
SNPs. For instance, ABCC1 SNP 5'FR/G-260C exhibited a very low MAF in our 
study population, thus investigation of this variant is suggested in a similar study on 
other ethnicities, such as Caucasians that show higher MAF for the SNP. 
Strengths of this study include the family based study that is robust against population 
substructure and confounding effects causing by population admixture and the case-
control study conducted in parallel with the family association study. It should also 
note that haplotype and linkage analysis were not performed for the polymorphisms 
that are in the same gene, as the aim of this study was to evaluate the role of the 
potentially functional SNPs as candidate disease susceptibility alleles and such 
analysis are irrelevant to this study.   
3.3 Conclusion 
 
ABCB1 polymorphisms at positions 2766, and 3435 appeared to be associated with 
susceptibility to orofacial clefting in the absence of multiple testing correction and the 
SNP C1236T was significantly associated even when type I error reduction was 
performed. However, no significant difference observed in distribution of maternal 
target SNPs alleles and genotypes in association with oral clefting in the offsprings. 
Thus, because of the fetal derivation of placental tissues, the P-gp genotype of the 
fetus is a critical factor in determining the degree of fetal exposure to substrates of this 
transport protein as well as the degree of the drugs teratogenicity. This also supports 
the hypothesis that the placental ABCB1/P-gp can influence the barrier function of 
this organ against teratogens. 
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Moreover, depending on the developmental toxicity profile of the Pg-p 
substrates/inhibitors, inhibition of the placental Pg-p activity may have deleterious 
effects on human fetal development. Thus, screening compounds or natural products 
to which women may be exposed during pregnancy for effects on placental Pg-p 
function or expression may be useful in protection of fetus, especially on the ground 
of ABCB1 polymorphisms at e12/1236, e21/2677, and e26/3435. This research also 
represents the importance of risk assessment for drug prescriptions in pregnancy and 
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